QUEST Provider Bulletin

Total Page:16

File Type:pdf, Size:1020Kb

QUEST Provider Bulletin HMSA Provider Bulletin HMS A ’ S P L an fo R Q U E S T M embe R S Bulletin Q08-01 January 15, 2008 A MESSAGE FROM OUR appointments, ensuring the collection and forwarding of MEDICAL DIRECTOR necessary information, obtaining prior authorizations, educating the parents, and following up to ensure appointments are kept is Children with Special Health Care Needs guaranteed to be difficult and time consuming. Children with chronic illnesses are Other examples include children with diabetes, congenital heart challenging for pediatricians and other defects, seizure disorders, asthma, cancer (even if in remission), primary care providers entrusted with and juvenile rheumatoid arthritis. Also included are children their care. This is especially so for with multiple diagnoses, related or otherwise. those children whose management The Hawaii Department of Health has a service dedicated to requires the services of various assisting such children, their families and their caregivers. This medical specialists, allied health care is the Children with Special Health Needs Program, under the providers, organizations, and institutions. A child with Family Health Services Division. Children and youth under 21 a cleft palate, for example, may require the services of years of age residing in Hawaii are eligible if they have chronic an ENT surgeon, oral surgeon, dentist, audiologist, health conditions lasting (or expected to last) at least one year, speech therapist, DME provider (for hearing aids), for which specialized medical care is required. and the Department of Education. Locating these The Children with Special Health Needs Program can assist providers, making the necessary referrals, coordinating QUEST members who are having difficulty in coordinating or obtaining health care services, or who cannot obtain certain Happy New Year 2008 services through QUEST, with the following: IN THIS ISSUE: • Coordination of health care referrals and appointments. This may include follow-up with PCPs, specialists, and other health • A Message from Our Medical Director care providers. • EPSDT Matters • Information about community services and resources, and help — Instructional DVDs Available to obtain these services. — Blood Lead Risk Questionnaire Discontinued • Social work services. — Dental Referrals • Nutrition consultations. — EPSDT Form Reminders For more information, you may contact a program representa- • Hospitalizations During Enrollment Changes tive at the following locations: • Claims Filing Information Oahu (main office) — Documentation for TPL Denials 741 Sunset Ave., Honolulu, HI 96816 • Drug Formulary Updates Phone: 733-9055 • Benefit Policies Fax: 733-9068 — Uterine Artery Embolization From Kauai (toll-free): 274-3141, ext. 39055# • Provider Handbook Updates From Maui (toll-free): 984-2400, ext. 39055# If you have any comments, questions or suggestions for our Bulletin, please call us at 948-6486 on Oahu or From Hawaii (toll-free): 974-4000, ext. 39055# 1 (800) 440-0640 toll-free from the Neighbor Islands. From Molokai/Lanai (toll-free): 1 (800) 468-4644, ext. 39055# P.O. Box 3520, Honolulu, HI 96811 - 3 5 2 0 • O a h u 9 4 8 - 6 3 2 1 • Neighbor Islands 1 (800) 77 1 - 0 6 7 7 Bulletin Q08-01 January 15, 2008 Continued from page 1 Kauai East Hawaii 3040 Umi St., Lihue, HI 96766 46 Keawe St., Hilo, HI 96720 Phone: 241-3376 Phone: 974-4288 Maui West Hawaii 54 High St., Wailuku, HI 96793 81-980 Halekii St. #103, Kealakekua, HI 96750 Phone: 984-2130 Phone: 322-4880 EPSDT MATTERS Program Requirements Reminder for PCPs Under Title XIX of the Social Security Act, the federally Lead risk assessments and blood lead levels are required mandated EPSDT program provides for comprehensive components at the specified ages. health services with emphasis on preventive care with If you have any questions, please call Provider early detection and timely treatment of problems for Services at 948-6486 or toll-free from the Neighbor Medicaid recipients. HMSA’s QUEST plan follows the Islands at 1 (800) 440-0640. You may also contact requirements set by Centers for Medicare and Medicaid Dr. Frank Smith, HMSA QUEST medical director, Services (CMS) and locally by DHS’ Med-QUEST at frank_smith@hmsa.com. Division for its EPSDT program. This includes utilizing Limited Number of Instructional DVDs Still Available the EPSDT forms (DHS 8015, 8015A and 8016) that were developed by Med-QUEST and ensuring that all If you missed the informational sessions on the new components of the EPSDT exam are performed and EPSDT forms, we still have a few DVDs of the state’s documented to receive the enhanced global reimburse- Med-QUEST session held last May at The Queen’s ment fee. Medical Center. The DVD can help you understand the forms and how to complete them. We can also send you As a PCP, you are contractually obligated to perform copies of the training materials we used at the HMSA EPSDT exams on members ages newborn through 20 informational sessions conducted last summer. years at intervals specified by the periodicity schedule. If you would like any of these training materials, All of the age-appropriate components listed on the call us at 948-6486 (Oahu) or toll-free at EPSDT form must be completed as part of the EPSDT 1 (800) 440-0640 (Neighbor Islands) Monday exam. Using the EPSDT code(s) on the CMS1500 through Friday between 7:45 a.m. and 4:30 p.m. claim form indicates that the required components were performed and documented on the form and in Blood Lead Risk Questionnaire Discontinued the member’s chart. Included as required components The Childhood Lead Risk Questionnaire, which was are vision and hearing screenings, immunization previously available through the state’s Childhood administration, intradermal placement of tuberculin Blood Lead Surveillance Program, is no longer available. testing material, and developmental and behavioral Therefore, you are no longer required to attach the assessments. These services are included in the global questionnaire to lab requisitions for blood lead testing. fee and cannot be paid separately. Verbal risk assessment, however, must continue to be Other preventive medicine or E/M services may not done for all EPSDT exams from age 6 months to 72 be substituted for EPSDT visits. months. 2 Bulletin Q08-01 January 15, 2008 Dental Referrals plan and transferred to the Medicaid fee-for-service program during the confinement. Dental services for children requiring dental care are provided through the Medicaid fee-for-service When a hospitalized member has an enrollment program. For help in finding a dental provider, change, the plan in which the member was enrolled parents can be referred to the Community Case on the date of admission remains financially Management Corporation at 792-1070, or toll-free responsible for the inpatient services as well as at 1 (888) 792-1070. transportation, lodging and meals for an attendant if required, through discharge as long as the member EPSDT Form Reminders remains in the same acute care facility. In the past, responsibility for inpatient confinements ended Attach only original (red ink) EPSDT forms to claims. when the patient’s level of care dropped. However, The new forms were developed to allow optical this condition no longer applies. Responsibility will scanning for data collection. Photocopies of the form remain with the plan/program until discharge. do not scan properly and will affect measurement of the effectiveness of the program and the type of care Professional services will continue to become intervention that ensures children receive needed care. the responsibility of the new plan/program upon Claims that are submitted with photocopies of the enrollment into the new plan/program, even if the EPSDT forms will be returned. confinement itself is still the responsibility of the plan/ program at time of admission. Only adjustment requests for claims that are being submitted for corrected processing will be accepted with photocopies of the EPSDT forms provided that CLAIMS FILING the original claim was submitted with a valid original EPSDT form. INFORMATION Provide written documentation for Clearly identify the provider conducting the exam. all third party insurance denials. Please legibly print the name of the provider who All other insurance denials must be documented by an conducted the screening exam. This should not be official written denial notice from the other insurance. the name of a clinic or facility. The provider’s This can be a copy of a dated termination letter from signature is also required as the form becomes a the other insurance to the member or the provider, a part of the patient’s medical record. claim denial report from the other insurance company Use your NPI. Be sure to use the NPI number instead to the provider showing the reason for the other of any HMSA legacy provider numbers. insurance denial, or a copy of the patient’s HIPAA Certificate of Coverage from the other insurance showing the termination date. HOSPITALIZATIONS The documentation must include the member DURING ENROLLMENT information and if it is a claim denial, it must indicate CHANGES the reason for no coverage. Notices that do not identify the member or that are not appropriate for Who is responsible? the claims in question are not sufficient and may The new benefit year that began Aug 1, 2007, result in denial of the claim. brought with it a change in the policy regarding who has responsibility for a patient’s confinement when a patient changes plans or is disenrolled from a QUEST 3 Bulletin Q08-01 January 15, 2008 DRUG FORMULARY UPDATES As announced in HMSA’s November 2007 Provider Update for pharmacies, the following changes to the QUEST formulary were effective Jan. 1, 2008, except where noted: Added to the formulary: Generic Name Brand Name Notes albuterol/ipratropium Generic DuoNeb aprepitant Emend trifold pack benzonatate Generic Tessalon carvedilol Generic Coreg darunavir Prezista exenitide Byetta SMBG test strips Freestyle Lite test strips insulin glargine Lantus Solostar Line extension eff.
Recommended publications
  • Targeted Radiotherapy of Brain Tumours
    British Journal of Cancer (2004) 90, 1469 – 1473 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Minireview Targeted radiotherapy of brain tumours ,1 MR Zalutsky* 1Department of Radiology, Duke University Medical Center, PO Box 3808, Durham, NC 27710, USA The utility of external beam radiotherapy for the treatment of malignant brain tumours is compromised by the need to avoid excessive radiation damage to normal CNS tissues. This review describes the current status of targeted radiotherapy, an alternative strategy for brain tumour treatment that offers the exciting prospect of increasing the specificity of tumour cell irradiation. British Journal of Cancer (2004) 90, 1469–1473. doi:10.1038/sj.bjc.6601771 www.bjcancer.com Published online 6 April 2004 & 2004 Cancer Research UK Keywords: glioblastoma multiforme; radiotherapy; radioimmunotherapy; glioma; anaplastic astrocytoma Even with aggressive multi-modality treatment strategies, the life present both on glioma as well as normal neural tissue (Hopkins expectancy for patients with glioblastoma multiforme (GBM), the et al, 1998). However, the vast majority of targeted radiotherapy most common and virulent primary brain tumour, is less than a studies in brain tumour patients have utilised radiolabelled mAbs year from the time of diagnosis (Stewart, 2002). The vast majority reactive with the tenascin molecule (Table 1). of glioma patients experience local recurrence, with a median survival of only 16–24 weeks for those with recurrent disease (Wong et al, 1999). Conventional radiotherapy continues to play a TENASCIN AND ANTI-TENASCIN MABS primary role in brain cancer treatment; however, its lack of tumour Tenascin-C is a hexabrachion polymorphic glycoprotein that is specificity is a severe limitation of this form of therapy.
    [Show full text]
  • Radiation Therapy – a Technicians Overview By: Stephanie Corsi, CVT
    Radiation Therapy – A technicians overview By: Stephanie Corsi, CVT Senior Radiation Oncology nurse, PennVet What is radiation therapy? Radiation therapy uses high-energy radiation or high energy particle (electrons) to kill cancer cells and shrink tumors. How does radiation therapy work? Radiation kills cancer cells by damaging their DNA. Cells that are rapidly dividing, like cancer cells, are more susceptible to radiation. The damage is by a high energy photon ejecting a high energy electron that then reacts with a water molecule to create charged particle, also called free radicals, within the cell that will damage the DNA. Most cells die what is called a “mitotic death”, meaning the cancer cells whose DNA is damaged beyond repair will stop dividing and die. Goal of Radiation: The purpose of radiation is to maximize the likelihood of tumor control while minimizing side-effects to the patient. Radiation may be used alone or in combination with surgery, chemotherapy, or both. “Curative” intent/ definitive therapy: This is given when the prognosis is good. The hope is that treatment will cure a cancer by eliminating a tumor and preventing recurrence. For tumors that are inherently sensitive, relatively small, and localized. Also used to treat residual cancer left behind after surgery, or before surgery to shrink a tumor. Examples: localized lymphomas, certain mast cell tumors, cutaneous squamous cell carcinomas Palliative intent: Not intended to cure, but rather relieve symptoms and reduce suffering. Given when prognosis is poor and quality of life is the primary focus. Used with bulky tumors. Examples: alleviate bone pain associated with osteosarcoma, a tumor pressing on the spine, tumors pressing on the esophagus interfering with breathing/eating, etc.
    [Show full text]
  • Clinical Outcomes and Prognostic Factors of Cyberknife Stereotactic
    Que et al. BMC Cancer (2016) 16:451 DOI 10.1186/s12885-016-2512-x RESEARCH ARTICLE Open Access Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma Jenny Que1*, Hsing-Tao Kuo2, Li-Ching Lin1, Kuei-Li Lin1, Chia-Hui Lin1, Yu-Wei Lin1 and Ching-Chieh Yang1 Abstract Background: Stereotactic body radiation therapy (SBRT) has been an emerging non-invasive treatment modality for patients with hepatocellular carcinoma (HCC) when curative treatments cannot be applied. In this study, we report our clinical experience with Cyberknife SBRT for unresectable HCC and evaluate the efficacy and clinical outcomes of this highly sophisticated treatment technology. Methods: Between 2008 and 2012, 115 patients with unresectable HCC treated with Cyberknife SBRT were retrospectively analyzed. Doses ranged from 26 Gy to 40 Gy were given in 3 to 5 fractions for 3 to 5 consecutive days. The cumulative probability of survival was calculated according to the Kaplan-Meier method and compared using log-rank test. Univariate and multivariate analysis were performed using Cox proportional hazard models. Results: The median follow-up was 15.5 months (range, 2-60 months). Based on Response Evaluation and Criteria inSolidTumors(RECIST).Wefoundthat48.7%ofpatients achieved a complete response and 40 % achieved a partial response. Median survival was 15 months (4-25 months). Overall survival (OS) at 1- and 2-years was 63. 5 %(54-71.5 %) and 41.3 % (31.6-50.6 %), respectively, while 1- and 2- years Progression-free Survival (PFS) rates were 42.8 %(33.0-52.2 %) and 38.8 % (29.0-48.4 %).
    [Show full text]
  • Accelerated Partial Breast Irradiation
    Continuing Medical Education societies regarding the definition of a Intracavitary balloon (Mammosite and Clinical evidence for partial- suitable candidate. Briefly, these include Contura) or strut-based brachytherapy breast irradiation early-stage, low-risk breast cancer: T1 or (SAVI) are another modality of breast The TARGIT, a phase III non- T2 invasive ductal breast carcinoma less brachytherapy. These devices come in The Department of Radiation Oncology offers free Continuing Medical Education credit to readers who read the inferiority trial, compared single-dose than 3 cm; estrogen positive; age greater different sizes, have single or multiple designated CME article and successfully complete a follow-up test online. You can complete the steps necessary targeted intraoperative radiotherapy than 60; and node negative12 (see Table lumens (strut-based or balloon-based to receive your AMA PRA Category 1 Credit(s)™ by visiting (TARGIT) versus fractionated external cme.utsouthwestern.edu/content/target-news- 1 for ASTRO consensus guidelines). catheters), and the entire device is placed beam radiotherapy (EBRT) for breast letter-accelerated-partial-breast-irradiation-apbi-options-and-new-horizons-em150 into the lumpectomy cavity. The lumens cancer.14 From 2000-2012, a total of Treatment options are then connected to an HDR unit, and 3,451 patients were randomized between Partial-breast radiation can be deliv- treatments are given twice daily for five APBI and whole-breast radiation in 33 ered via several different modalities, days to a dose of 34 Gy in 10 fractions. centers in 11 countries. Fifteen percent including interstitial brachytherapy, This treatment is invasive, and the device of women in the APBI arm were treated Accelerated partial breast irradiation (APBI): intracavitary brachytherapy (SAVI, stays within the lumpectomy cavity for the with additional EBRT due to adverse Contura, or Mammosite), intraopera- duration of the radiation treatments (five pathological features.
    [Show full text]
  • (IORT) for Surgically Resected Brain Metastases: Outcome Analysis of an International Cooperative Study
    Journal of Neuro-Oncology https://doi.org/10.1007/s11060-019-03309-6 CLINICAL STUDY Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study Christopher P. Cifarelli1,3 · Stefanie Brehmer5 · John Austin Vargo2 · Joshua D. Hack3 · Klaus Henning Kahl4 · Gustavo Sarria‑Vargas6 · Frank A. Giordano6 Received: 19 August 2019 / Accepted: 5 October 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Background and objective The ideal delivery of radiation to the surgical cavity of brain metastases (BMs) remains the subject of debate. Risks of local failure (LF) and radiation necrosis (RN) have prompted a reappraisal of the timing and/or modality of this critical component of BM management. IORT delivered at the time of resection for BMs requiring surgery ofers the potential for improved local control (LC) aforded by the elimination of delay in time to initiation of radiation following surgery, decreased uncertainty in target delineation, and the possibility of dose escalation beyond that seen in stereotactic radiosurgery (SRS). This study provides a retrospective analysis with identifcation of potential predictors of outcomes. Methods Retrospective data was collected on patients treated with IORT immediately following surgical resection of BMs at three institutions according to the approval of individual IRBs. All patients were treated with 50kV portable linear accelerator using spherical applicators ranging from 1.5 to 4.0 cm. Statistical analyses were performed using IBM SPSS with endpoints of LC, DBC, incidence of RN, and overall survival (OS) and p < 0.05 considered signifcant. Results 54 patients were treated with IORT with a median age of 64 years.
    [Show full text]
  • PRIOR AUTHORIZATION for RADIATION THERAPY For
    PRIOR AUTHORIZATION for RADIATION THERAPY For authorization, please complete this form, include patient chart notes to document information and FAX to the PEHP Prior Authorization Department at (801) 366‐7449 or mail to: 560 East 200 South Salt Lake City, UT 84102. If you have prior authorization or benefit questions, please call PEHP Customer Service at (801) 366‐7555 or toll free at (800) 753‐7490. Section I: PATIENT INFORMATION Name (Last, First MI): DOB: Age: PEHP ID #: Section II: PROVIDER INFORMATION Date Requested: Service Provider Name: Service Provider NPI #: Service Provider Tax ID #: Service Provider Address: Contact Person: Phone: Facsimile: ( ) ( ) Section III: PRE-AUTHORIZATION REQUEST Nature of Request: Please check. Requested Date (s) of Service: Place of Service: Please check. Auth Extension Pre‐Auth Retro Auth Urgent Ambulatory Surgical Center Inpatient Office Outpatient Facility Name: Facility NPI #: Facility Tax ID #: Facility Address: Facility Phone: Facility Facsimile: ( ) ( ) Primary Diagnosis/ICD‐10 Code: Secondary Diagnosis/ICD‐10 Code: A. Stage of Disease (T, N, M): B. Metastatic Site (s): N/A C. Karnofsky/ECOG Score: D. Indication for Radiation Therapy: Please check. Adjuvant Chemoradiation Consolidative Curative Neoadjuvant Palliative Other (please specify): ___________________________ E. Type of Radiation Modality/Technique Being Requested: Please check all that apply. 1. Accelerated 2. Accelerated‐Fractionated 3. Accelerated Partial Breast Irradiation (APBI) 4. Accelerated Whole Breast Irradiation/AWBI 5. Boost 6. Conformal/3D (3D‐CRT) 7. Conventional/2D (2DRT) 8. External Beam/EBRT 9. High Dose/HDR Brachytherapy 10. Hyperfractionated (or Superfractionated) 11. Hypofractionated 12. Image Guided/IGRT 13. Intensity Modulated/IMRT 14. Internal (Brachytherapy) 15. Interstitial Brachytherapy 16.
    [Show full text]
  • Immunoscintigraphy and Radioimmunotherapy in Cuba: Experiences with Labeled Monoclonal Antibodies for Cancer Diagnosis and Treatment (1993–2013)
    Review Article Immunoscintigraphy and Radioimmunotherapy in Cuba: Experiences with Labeled Monoclonal Antibodies for Cancer Diagnosis and Treatment (1993–2013) Yamilé Peña MD PhD, Alejandro Perera PhD, Juan F. Batista MD ABSTRACT and therapeutic tools. The studies conducted demonstrated the good INTRODUCTION The availability of monoclonal antibodies in Cuba sensitivity and diagnostic precision of immunoscintigraphy for detect- has facilitated development and application of innovative techniques ing various types of tumors (head and neck, ovarian, colon, breast, (immunoscintigraphy and radioimmunotherapy) for cancer diagnosis lymphoma, brain). and treatment. Obtaining different radioimmune conjugates with radioactive isotopes OBJECTIVE Review immunoscintigraphy and radioimmunotherapy such as 99mTc and 188Re made it possible to administer radioimmuno- techniques and analyze their use in Cuba, based on the published lit- therapy to patients with several types of cancer (brain, lymphoma, erature. In this context, we describe the experience of Havana’s Clini- breast). The objective of 60% of the clinical trials was to determine cal Research Center with labeled monoclonal antibodies for cancer pharmacokinetics, internal dosimetry and adverse effects of mono- diagnosis and treatment during the period 1993–2013. clonal antibodies, as well as tumor response; there were few adverse effects, no damage to vital organs, and a positive tumor response in a EVIDENCE ACQUISITION Basic concepts concerning cancer and substantial percentage of patients. monoclonal antibodies were reviewed, as well as relevant inter- national and Cuban data. Forty-nine documents were reviewed, CONCLUSIONS Cuba has experience with production and radiola- among them 2 textbooks, 34 articles by Cuban authors and 13 by beling of monoclonal antibodies, which facilitates use of these agents.
    [Show full text]
  • Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
    CCR FOCUS Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends Martina Steiner and Dario Neri Abstract When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible. Monoclonal antibodies and their fragments, labeled with therapeutic radionuclides, have been used for many years in the development of anticancer strategies, with the aim of concentrating radioactivity at the tumor site and sparing normal tissues. This review surveys important milestones in the development and clinical implementation of radioimmunotherapy and critically examines new trends for the antibody-mediated targeted delivery of radionuclides to sites of cancer. Clin Cancer Res; 17(20); 6406–16. Ó2011 AACR. Introduction are immunogenic in humans and thus prevent repeated administration to patients [this limitation was subse- In 1975, the invention of hybridoma technology by quently overcome by the advent of chimeric, humanized, Kohler€ and Milstein (1) enabled for the first time the and fully human antibodies (7)]. Of more importance, production of rodent antibodies of single specificity most radioimmunotherapy approaches for the treatment (monoclonal antibodies). Antibodies recognize the cog- of solid tumors failed because the radiation dose deliv- nate
    [Show full text]
  • The Future of Radiation Therapy Safe and Innovative Options, Including the Cyberknife® System
    The future of radiation therapy Safe and innovative options, including the CyberKnife® System Could a nonsurgical treatment be right for you? When you’ve been diagnosed with a cancerous or noncancerous tumor, it’s natural to have questions and concerns about your treatment options. While surgery is sometimes the recommended treatment, in many cases, there are nonsurgical options. At CyberKnife® of Long Island, we offer noninvasive radiation therapy treatments that provide benefits over traditional surgery, including: – More comfort – Better accuracy – Fewer side effects – Quicker recovery times With two locations in western Suffolk, our services are also close to home. You have an experienced and Gain the advantage of trusted team dedicated to comprehensive, innovative care your treatment CyberKnife of Long Island is part of the At CyberKnife of Long Island, you can be Northwell Health Cancer Institute, one of confident that you’re being treated by the largest cancer programs in the New York experts in cancer care. metropolitan area. – For almost two decades (originally as We work with a wide range of cancer North Shore Radiation Therapy), we have specialists (nearly 200 members in over been using innovative technology to 25 different specialties). treat a wide variety of cancers, including prostate, lung, brain, skin, breast, head Patients have access to a robust research and and neck, spinal and rectal tumors. clinical trials program and an array of cancer support services — as well as a vast range of – We are the first in Suffolk County to primary care physicians, specialists, emergency use CyberKnife and have been treating rooms, imaging centers, laboratories, home patients with the technology since care and hospice.
    [Show full text]
  • Getting Oral Or Systemic Radiation Therapy
    cancer.org | 1.800.227.2345 Getting Oral or Systemic Radiation Therapy What is systemic radiation therapy? Systemic therapy involves treatment that travels through your entire body rather than being aimed at one area. Systemic radiation therapy uses radioactive drugs (called radiopharmaceuticals or radionuclides) to treat certain types of cancer, including thyroid, bone, and prostate cancer. These are liquid drugs made up of a radioactive substance. They can be given by mouth or put into a vein; they then travel throughout the body. Although these drugs travel through your whole body, they can find and collect in places where the cancer cells are located. This helps them deliver radiation doses exactly to the tumor or area where the cancer cells are found. In some cases, a radioactive drug might be used to help find cancer, such as bone metastasis (when cancer has spread to the bone). There are also radioactive drugs that are used to help diagnose other non-cancer health problems. Radioimmunotherapy One type of radiopharmaceutical is called radioimmunotherapy. This treatment combines a small amount of radioactive material with a special drug called a monoclonal antibody1. The radioactive material acts as a tracer that can find and attach to cancer cells, then the monoclonal antibody is delivered directly to the cells. Peptide receptor radionuclide therapy (PRRT) Another type of radiopharmaceutical is called peptide receptor radionuclide therapy (PRRT). This treatment combines radioactive material with a special protein called a peptide to make a radiopeptide. When given, the radiopeptide finds and attaches to 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 certain types of cancer cells, then delivers a high dose of radiation directly to the cells.
    [Show full text]
  • Cyberknife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy
    ORIGINAL RESEARCH ARTICLE published: 21 March 2012 doi: 10.3389/fonc.2012.00025 CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy Jonathan Andrew Haas 1*, Matthew R. Witten2, Owen Clancey 2, Karen Episcopia2, Diane Accordino1 and Eva Chalas 3 1 Division of Radiation Oncology, Winthrop-University Hospital, Mineola, NY, USA 2 Division of Medical Physics, Winthrop-University Hospital, Mineola, NY, USA 3 Division of Gynecologic Oncology, Winthrop-University Hospital, Mineola, NY, USA Edited by: Standard radiation therapy for patients undergoing primary chemosensitized radiation for Brian Timothy Collins, Georgetown carcinomas of the cervix usually consists of external beam radiation followed by an intra- Hospital, USA cavitary brachytherapy boost. On occasion, the brachytherapy boost cannot be performed Reviewed by: Sean Collins, Georgetown University due to unfavorable anatomy or because of coexisting medical conditions. We examined the Hospital, USA safety and efficacy of using CyberKnife stereotactic body radiotherapy (SBRT) as a boost Brian Timothy Collins, Georgetown to the cervix after external beam radiation in those patients unable to have brachytherapy Hospital, USA to give a more effective dose to the cervix than with conventional external beam radiation *Correspondence: alone. Six consecutive patients with anatomic or medical conditions precluding a tandem Jonathan Andrew Haas, Division of Radiation Oncology, and ovoid boost were treated with combined external beam radiation and CyberKnife boost Winthrop-University Hospital, 264 Old to the cervix. Five patients received 45 Gy to the pelvis with serial intensity-modulated radi- Country Road, Mineola, NY 11501, ation therapy boost to the uterus and cervix to a dose of 61.2Gy.These five patients received USA.
    [Show full text]
  • Releasing Nuclear Medicine Patients to the Public
    Educational Objectives • Introduce participants to the medical conditions that are Releasing Nuclear Medicine treated with radioiodine. • Review the regulatory considerations regarding Patients to the Public: inpatient and outpatient radioiodine procedures. Dose Calculations and Discharge • Review ways in which the regulatory requirements may be satisfied, including “public” radiation dose Instructions computations, content of post-discharge instructions and addressing the concerns of patients and their families. Robert E. Reiman, MD Radiation Safety Division • Introduce Web-based methods to facilitate Duke University Medical Center documentation of outpatient treatment. Durham, NC Medically Useful Iodine Isotopes Treatment of Toxic Goiter Isotope Half-life Primary Use Emissions I-123 13.3 hours γ (0.158 MeV) Diagnosis • Surgery (not done, except for very large thyroid, low iodine uptake, cancer or I-124 4.2 days β+ and γ (0.511 Diagnosis, pregnancy) MeV +) Therapy(?) I-125 59.4 days γ (0.035 MeV) Brachytherapy • Drugs (propylthiouracil) and beta blockers (short-term) I-131 8.0 days β- (0.606 MeV), Diagnosis, • Ablation with radioactive iodine γ (0.364 MeV) Therapy Radioiodine Treatment Thyroid Carcinoma • I-131 sodium iodide solution, orally • 8 – 15 millicuries for diffuse toxic goiter • Incidence: about 3 per 100,000 per year • 15 – 40 millicuries for toxic multinodular • Females > Males (2:1) goiter • About 80% papillary type; remainder • Must know the % uptake at 24 hours to follicular or medullary types. compute administered activity and • Medullary thyroid carcinoma does not clearance rates take up radioiodine. 1 Diagnosis of Thyroid Treatment of Thyroid Carcinoma Carcinoma • Surgical removal of thyroid gland and • Usually asymptomatic except for a dissection of local lymph nodes.
    [Show full text]